BioMarin Pharma (BMRN) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.50 +1.07%
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $449.8 million versus the consensus estimate of $442.09 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion, versus the consensus of $2.14 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
